Molecular Pharming: Plant-Based Production of Vaccines and Biologics

Amara Zafar[1*], Bushra Sadia[2], Imshal Azam[2], Muhammad Arslan Khalil[2], Areeka Batool[2] and Saleha Tahir[3]

1. Department of Botany, University of Agriculture Faisalabad, Pakistan
2. Centre of Agricultural Biochemistry and Biotechnology, University of Agriculture Faisalabad, Pakistan
3. Department of Parasitology, University of Agriculture Faisalabad, Pakistan

*Corresponding Author: **amarazafar75@gmail.com**

ABSTRACT

Molecular farming is a novel biotechnology employing plants as biofactories for the manufacture of vaccines and biologics. Compared with conventional means such as mammalian cell culture or microbial fermentation, plant-based systems provide lower-cost, high-throughput, and safer approaches. Expression platforms like transient expression, stable transformation, and chloroplast engineering can be used for quick, high-yield recombinant protein production. Plant-based vaccines have been promising in infectious diseases, cancer immunotherapy, and veterinary medicine, with examples such as Medicago's COVID-19 vaccine. Advantages are lower costs, decreased risk of contamination, and oral delivery possibilities through edible vaccines. Plant-based systems also offer an instant pandemic response and are environmentally friendly. Challenges such as purification complexities of proteins, regulatory challenges, and public distrust of genetically modified plants slow down widespread implementation. The problems are to be addressed by standard production, next-generation genetic tools, and regulation reform. Plant-based vaccines have the potential to become a significant player in world health with continued development, with vaccine access and equitable distribution improving.

Keywords: Molecular Farming, Plant-based vaccines, Mechanism, Challenges

To cite this article: Zafar A, B Sadia, I Azam, MA Khalil, A Batool & S Tahir. Molecular Pharming: Plant-Based Production of Vaccines and Biologics. Biological Times. 2025. March 4(3): 46-47.

Introduction

Molecular farming utilizes crop plants to yield valuable proteins including recombinant antibodies, plasma proteins, and enzymes, and to revolutionize vaccine production [1]. In contrast to conventional processes such as microbial fermentation and mammalian cell culture. This is achieved through chloroplast engineering and transient expression systems. Transient expression commonly with *Agrobacterium tumefaciens* provides for quick production cycles and is well suited to pandemic situations. One milestone was the regulatory approval of plant-based Covifenz, a COVID-19 vaccine in Canada. Molecular farming has also been applied to veterinary vaccines and edible vaccines in plants such as lettuce or tomatoes, avoiding cold-chain requirements and enhancing availability in resource-constrained regions [2].

Molecular farming makes plant-based vaccine production innovative because it overcomes the limitations of traditional methods [3]. It is cost-effective, scalable, and does not require expensive bioreactors, making it suitable for low- and middle-income countries. The advantage of not having human pathogen contamination like mammalian cell systems makes the plants safe. Plant cell cultures provide exact post-translational modifications required for biopharmaceuticals along with regulated, year-round production with high protein output. Further developments in genetic technologies improve output by use of CRISPR among others. Plant-based sustainable vaccinations provide big-scale rapid manufacturing abilities during pandemics and generate lower carbon footprints than other alternatives. Molecular farming acts as a key health equality tool due to its capacity to reduce vaccine prices while improving global access to medical services [4]. The research provides extensive details about plant-derived vaccines by discussing major advances together with their achievements and hurdles in addition to projected developments.

Mechanism of Molecular Farming

1. Plant Expression Systems

The production of recombinant proteins together with vaccines relies on plant expression systems as essential molecular farming tools. The main approaches to producing recombinant proteins are transient expression and stable transformation while each method offers different advantages [5]. The generation of proteins in short development periods uses A. t*umefaciens* and virus vectors in transient expression. PVX-based vectors allow both economical and scalable production of vaccines through their vectored vaccine technology systems. The method of stable transformation allows continuous protein synthesis through integration of the gene of interest into the plant genome. Plants transformed through chloroplast or nuclear techniques deliver both reduced transgenes escape risks and enhanced expression stability and levels of transgenes in the system. The method of quick expression enables convenient processes while stable transformation enables large-scale manufacturing of products [6]. The integration of different expression systems establishes a productive method for plant-based vaccine manufacturing that can address diseases including cholera, TB, and anthrax.

2. Plant Host Molecular Farming

The efficiency and cost-efficiency of recombinant protein synthesis through molecular farming depend heavily on the quality of host plants. Four frequently chosen host plants including maize, tomatoes, lettuce and tobacco present different operational strengths and limitations [7].

3. Commonly used Plants

The agricultural practice of molecular farming uses tobacco plants mainly because of their effective biomass generation and genetic modification potential alongside their adaptability to transient expression systems. The manufacturing process of vaccines needs good purification systems because of this plant material's composition [8]. The plant Lactuca sativa shows promise as an edible vaccine host because it delivers oral antigen antigens through unprocessed produce. The manufacturing process of vaccines benefits from tomato plants (Solanum lycopersicum) because they efficiently produce high levels of recombinant proteins [9]. Mass production of therapeutic proteins needs the use of Zea mays also known as maize. Seeds from this plant provide a natural method to pack products for direct oral use. The main limitations of this approach include gene flow threats that diminish the transformation process effectiveness [10].

Plant-Based Vaccine Applications

1. Edible Vaccines

Edible vaccines, produced in plants like potatoes, tomatoes, lettuce, and bananas, offer a favorable solution for low-resource settings lacking old vaccine organization. However, challenges include inconsistent antigen expression due to variable growing conditions, difficulty in delivering precise doses, and antigen degradation during storage and digestion [11]. To improve stability and efficacy strategies such as freeze-drying plant material. While consuming raw edible plants may help stabilize antigens, processed forms like powders and capsules offer better dosage control.

2. Therapeutic Plant-Based Vaccines

Therapeutic plant-based vaccines stimulate immune responses to treat diseases such as cancer, chronic infections, and autoimmune disorders. Unlike prophylactic vaccines, they introduce disease-specific antigens to control immune function [12]. For chronic infections, plant-based vaccines introduce pathogen proteins to activate cytotoxic T lymphocytes (CTLs) to kill cancer cells. Remarkably, HER2 and mucin-1 vaccine candidates have been promising in preclinical cancer research. A Phase I clinical trial proved the practicability, safety, and immunogenicity of plant-made idiotype vaccines for non-Hodgkin's lymphoma, making individualized immunotherapy possible [13]. For autoimmune diseases like multiple sclerosis and type 1 diabetes, plant vaccines induce immune tolerance by presenting self-antigens. Oral administration is directed at the gutassociated lymphoid tissue (GALT) to activate regulatory T cells and minimize immune destruction. This approach has also been tested for allergies, inflammatory bowel disease, Alzheimer's, and cardiovascular disease [14]. Plant-based vaccines are also in the process of being developed for chronic infectious diseases like HIV and tuberculosis. HIV vaccines employ envelope glycoproteins to induce neutralizing antibodies and CTL responses, whereas tuberculosis vaccines present major *Mycobacterium tuberculosis* antigens to augment the Th1 immune response [15].

Plant-Based Vaccines Benefits

1. Scalability and Cost Effectiveness

Plant-based vaccines function as an alternative manufacturing solution to more expensive conventional methods which require bioreactors along with expensive facilities. *N. benthamiana* together with *N. tabacum* enable plant expression systems that produce vaccines through affordable means requiring basic facilities to operate either in open fields or under greenhouse conditions. Large-scale vaccine production can be achieved with these systems that utilize small amounts of resources in addition to enabling local cultivation which minimizes expenses for transport and cold storage. Edible vaccines lower costs because they eliminate expensive delivery techniques together with their associated benefits. The manufacture of vaccines using plant-based methods presents an economical solution which maintains environmental sustainability for mass production serving human and animal populations [16].

2. Emerging Diseases and Rapid Response to Pandemics

Plant-based vaccines manufacture at a much faster rate compared to contemporary methods using mammalian cells or avian eggs when addressing pandemics and emerging health problems. Greenhouses together with plant factories allow scientists to control growing conditions for indoor crops which produce reproducible output at large scales throughout the entire year with minimized contamination risks. The procedures aid quality assessment processes and simplify regulatory protocols and make it possible to rapidly adapt to new pathogens after genetic modifications. This rapid manufacturing capability is crucial to delivering timely responses to epidemics by effectively stopping the spread of infectious diseases [17].

3. Less Risk of Human Pathogen Contamination

Since plants are innately resistant to human illnesses, plant-based immunizations provide a safer solution by lowering the potential for contamination. They alleviate ethical concerns and limit the probability of zoonotic disease transmission as they do not involve animal-derived materials like fetal bovine serum, unlike traditional procedures. The plant-based systems functionality allows for speedy control over extensive vaccine production at big scales. Production systems ensure safety alongside scalable characteristics and ethical practices that make them suitable for worldwide healthcare programs [18].

Plant-Based Vaccine Development Challenges

1) Assembly Challenges

Low protein yields and issues with scalability and homogeneity in transient expression systems hinder the production of plant-based vaccines, and protein expression levels fluctuate in plant systems due to environmental influences like temperature, light, and soil quality, unlike closely regulated mammalian cell cultures. One of the main challenges in the production of plant-based vaccines is the uniformity of protein expression, which varies depending on the growing conditions, plant host, and transformation techniques [19].

2) Downstream Processing

A major obstacle to the advancement of plant-based vaccines is downstream processing since protein purification is costly and difficult. Extracting and purifying recombinant proteins from plant matrices requires separating the target antigen from other plant components, which makes the procedure expensive and time-consuming. Additionally, the glycosylation patterns of plant-derived proteins vary, influencing the immune response and antigen function. Variations in plant growth conditions make standardization difficult which causes differences in every manufactured vaccine batch. Strict quality control measures together with optimized purification processes must be established for plant-based vaccines to reach their production effectiveness [20].

3) Regulatory Hurdles

Standard commercialization procedures for evaluating safety and environmental effects and allergenicity of transgenic plants do not exist at the European Medicines Agency (EMA) alongside the Food and Drug Administration (FDA). The approval of GMOs remains crucial because strict regulations need comprehensive testing at all stages before market release. The existing regulatory structures representing a basic problem for plant-based vaccine development since conventional vaccine frameworks already exist. The clearance procedures together with their associated costs create delays that retard the market entry of plant-based vaccine products [21].

4) Public Acceptance

The public does not accept genetically modified plants due to ethical issues and social misunderstandings which creates obstacles for plant-based immunizations. Misinformation, opposition to artificial food sources, and blurring of boundaries between GMOs in food and biopharmaceuticals are among the factors for distrust. To refute myths and create educated conversations regarding the benefits and safety of plant-based immunizations, it is vital to educate the public via open communication, education, and scientific outreach [22].

Conclusion

Molecular farming utilizes an advanced vaccine method that enables plants to function as biofactories to create immunizations through a secure large-scale inexpensive manufacturing process. The production of plant vaccines through stable transformation or transitory expression provides new vaccination alternatives suitable for veterinary medicine and cancer immunotherapy treatment of infectious infections. The production process saves money while disease responses speed up and the risk of infectious contamination decreases alongside better service access reaching areas with restricted resources. The challenge of public acceptance stands as the primary difficulty despite existing problems in uniform glycosylation and GMO GMOS licensing process and GMO purification as well as GMO protein expression optimization. Current misunderstandings should be refuted through education and outreach campaigns to resolve the situation. The possibility of producing COVID-19 vaccines from yeast cells is likely to improve through discoveries in genetic engineering as well as advances in manufacturing methods combined with regulatory adjustments.

References

[1] Shanmugaraj B, I Bulaon CJ, Phoolcharoen W. Plant molecular farming: a viable platform for recombinant biopharmaceutical production. Plants. 2020 Jul; 9 (7):842.

[2] Sahoo A, Mandal AK, Dwivedi K, Kumar V. A cross talk between the immunization and edible vaccine: Current challenges and future prospects. Life Sciences.2020 Nov 15; 261:118343.

[3] Rybicki EP. Plant molecular farming of virus‐like nanoparticles as vaccines and reagents. Wiley Interdisciplinary Reviews: Nan medicine and Nano-biotechnology.2020 Mar; 12 (2):e1587.

[4] Shin MD, Shukla S, Chung YH, Beiss V, Chan SK, Ortega-Rivera OA, Wirth DM, Chen A, Sack M, Pokorski JK, Steinmetz NF. COVID-19 vaccine development and a potential nanomaterial path forward. Nature nanotechnology.2020 Aug; 15 (8):646-55.

[5] Eidenberger L, Kogelmann B, Steinkellner H. Plant-based biopharmaceutical engineering. Nature Reviews Bioengineering. 2023 Jun; 1 (6):426-39.

[6] Kumar AU, Ling AP. Gene introduction approaches in chloroplast transformation and its applications. Journal of Genetic Engineering and Biotechnology. 2021 Dec; 19:1-0.

[7] Shahid, N.; Daniell, H. Plant-based oral vaccines against zoonotic and non-zoonotic diseases. Plant Biotechnology J. 2016, 14, 2079–2099.

[8] Mirzaee M, Osmani Z, Frébortová J, Frébort I. Recent advances in molecular farming using monocot plants. Biotechnology Advances.2022 Sep 1; 58:107913.

[9] Liu H, Timko MP. Improving protein quantity and quality—the next level of plant molecular farming. International Journal of Molecular Sciences.2022 Jan 25; 23 (3):1326.

[10] Clark M, Maselko M. Transgene biocontainment strategies for molecular farming. Frontiers in Plant Science. 2020 Mar 3; 11:210.

[11] Klojdová I, Milota T, Smetanová J, Stathopoulos C. Encapsulation: a strategy to deliver therapeutics and bioactive compounds? Pharmaceuticals.2023 Feb 27; 16 (3):362.

[12] Abbas RZ, Qureshi MA, Saeed Z. Botanical compounds: A promising control strategy against Trypanosoma cruzi. Boletín Latinoamericano y del Caribe de Plantas Medicinales y Aromáticas. 2025 Jan 5;24(3):308-27.

[13] Hamley I. W. (2022). Peptides for Vaccine Development. ACS Applied Biomaterials, 5(3), 905–944.

[14] Ishiura S, Yoshida T. Plant-based vaccines for Alzheimer's disease. Proceedings of the Japan Academy, Series B. 2019 Jun 11; 95 (6):290-4.

[15] Kim H, Kwon KW, Park J, Kang H, Lee Y, Sohn EJ, Hwang I, Eum SY, Shin SJ. Plant-produced N-glycosylated Ag85A exhibits enhanced vaccine efficacy against Mycobacterium tuberculosis HN878 through balanced multifunctional Th1 T cell immunity. Vaccines.2020 Apr 18; 8(2):189.

[16] Bamakan SM, Moghaddam SG, Manshadi SD. Blockchain-enabled pharmaceutical cold chain: Applications, key challenges, and future trends. Journal of Cleaner Production 2021 Jun 15; 302:127021.

[17] Cid R, Bolívar J. Platforms for production of protein-based vaccines: from classical to next-generation strategies. Biomolecules.2021 Jul 21; 11 (8):1072.

[18] Moon KB, Park JS, Park YI, Song IJ, Lee HJ, Cho HS, Jeon JH, Kim HS. Development of systems for the production of plant-derived biopharmaceuticals. Plants.2019 Dec 24; 9 (1):30.

[19] Kumar AU, Kadiresen K, Gan WC, Ling AP. Current updates and research on plant-based vaccines for coronavirus disease 2019. Clinical and Experimental Vaccine Research.2021 Jan 31; 10 (1):13.

[20] Gutierrez-Valdes N, Cunyat F, Balieu J, Walet-Balieu ML, Paul MJ, de Groot J, Blanco-Perera A, Carrillo J, Lerouge P, Jansma-van Seters M, Joensuu JJ. Production and characterization of novel Anti-HIV Fc-fusion proteins in plant-based systems: Nicotiana benthamiana & tobacco BY-2 cell suspension. New Biotechnology.2024 Nov 25; 83: 142-54.

[21] Ghimire BK, Yu CY, Kim WR, Moon HS, Lee J, Kim SH, Chung IM. Assessment of benefits and risk of genetically modified plants and products: current controversies and perspective. Sustainability.2023 Jan 16; 15 (2):1722.

[22] Bird RC. Anti-GMO and vaccine-autism public policy campaigns in the court of public opinion. Hastings LJ.2020; 72:719.